tagline banner banner


Carigent Awarded NSF Phase I SBIR Grant



The Carigent drug delivery platform allows for sustained-release of therapeutic agents, targeting of therapy to a particular physiological site, tethering of surface ligands, and the ability to combine multiple agents into one vehicle made primarily from FDA approved materials. The technology is unique as it combines well-characterized, safe materials with a novel method of adhering a high density of ligands to the surface which allow:

  • delivery of multiple therapeutic modalities such as RNAi, peptides, small molecules and therapeutic vaccines
  • flexibility in targeting the drug delivery system for a variety of disease states and delivery routes
  • enhancement of in vivo circulation times

We are aggressively pursuing a comprehensive product pipeline in multiple therapeutic areas including cancer treatment, antibody therapeutics, and RNAi delivery both internally and in collaboration with pharmaceutical and biotechnology industry leaders.